MX2020010673A - Formulaciones de apixaban. - Google Patents

Formulaciones de apixaban.

Info

Publication number
MX2020010673A
MX2020010673A MX2020010673A MX2020010673A MX2020010673A MX 2020010673 A MX2020010673 A MX 2020010673A MX 2020010673 A MX2020010673 A MX 2020010673A MX 2020010673 A MX2020010673 A MX 2020010673A MX 2020010673 A MX2020010673 A MX 2020010673A
Authority
MX
Mexico
Prior art keywords
apixaban
apixaban formulations
formulations
formulation
treatment
Prior art date
Application number
MX2020010673A
Other languages
English (en)
Inventor
Sherif Ibrahim Farag Badawy
Timothy D Stevens
Daniel Kuntz
Brett Waybrant
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2020010673A publication Critical patent/MX2020010673A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona la formulación farmacéutica de apixaban. También se proporciona un uso de la formulación de apixaban en el tratamiento de un trastorno tromboembólico.
MX2020010673A 2018-04-16 2019-04-15 Formulaciones de apixaban. MX2020010673A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862658175P 2018-04-16 2018-04-16
PCT/US2019/027456 WO2019204193A1 (en) 2018-04-16 2019-04-15 Apixaban formulations

Publications (1)

Publication Number Publication Date
MX2020010673A true MX2020010673A (es) 2020-10-28

Family

ID=66429558

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010673A MX2020010673A (es) 2018-04-16 2019-04-15 Formulaciones de apixaban.

Country Status (15)

Country Link
US (1) US11896586B2 (es)
EP (2) EP3781132B1 (es)
JP (1) JP7382957B2 (es)
AU (1) AU2019255599B2 (es)
BR (1) BR112020020941A2 (es)
CA (1) CA3097176A1 (es)
DK (1) DK3781132T3 (es)
FI (1) FI3781132T3 (es)
LT (1) LT3781132T (es)
MX (1) MX2020010673A (es)
PL (1) PL3781132T3 (es)
PT (1) PT3781132T (es)
RS (1) RS65428B1 (es)
SG (1) SG11202010097WA (es)
WO (1) WO2019204193A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202140003A (zh) * 2020-02-13 2021-11-01 大陸商江蘇恒瑞醫藥股份有限公司 阿哌沙班注射劑用於預防或者治療血栓栓塞的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU670567B2 (en) * 1992-03-05 1996-07-25 American Home Products Corporation Pharmaceutical coated cores
PT969821E (pt) * 1997-03-26 2003-10-31 Janssen Pharmaceutica Nv Pastilhas tendo um nucleo revestido com um antifungico e um polimero
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AU2010260208B2 (en) 2009-06-16 2014-11-13 Bristol-Myers Squibb Holdings Ireland Unlimited Company Dosage forms of apixaban
EP2538925B1 (en) 2010-02-25 2015-12-16 Bristol-Myers Squibb Company Apixaban formulations
EP2554159A1 (en) * 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
MX351059B (es) * 2012-08-17 2017-09-29 Laboratorios Senosiain S A De C V Star Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
EP2900217A1 (en) * 2012-09-26 2015-08-05 Bristol-Myers Squibb Company Apixaban liquid formulations
CN105663049A (zh) 2014-11-22 2016-06-15 哈尔滨圣吉药业股份有限公司 一种阿哌沙班缓释微丸及其制备方法
US10413543B2 (en) * 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
CN106913528A (zh) * 2015-12-25 2017-07-04 中美华世通生物医药科技（武汉）有限公司 阿哌沙班微丸及其制备方法

Also Published As

Publication number Publication date
EP3781132B1 (en) 2024-03-20
CA3097176A1 (en) 2019-10-24
RS65428B1 (sr) 2024-05-31
FI3781132T3 (fi) 2024-05-31
EP4353312A2 (en) 2024-04-17
PL3781132T3 (pl) 2024-05-20
EP3781132A1 (en) 2021-02-24
SG11202010097WA (en) 2020-11-27
AU2019255599B2 (en) 2024-02-29
US11896586B2 (en) 2024-02-13
BR112020020941A2 (pt) 2021-03-02
JP2021521242A (ja) 2021-08-26
US20210145817A1 (en) 2021-05-20
AU2019255599A1 (en) 2020-11-12
WO2019204193A1 (en) 2019-10-24
JP7382957B2 (ja) 2023-11-17
LT3781132T (lt) 2024-04-25
PT3781132T (pt) 2024-05-16
DK3781132T3 (da) 2024-04-22

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
CA2956871C (en) Compounds active towards bromodomains
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12017500494A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
CL2015002897A1 (es) Inhibidores de bace1
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP4324824A3 (en) Combination antibacterial composition and short-course antibacterial regimen
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
GEP20196977B (en) Pharmaceutical formulations of vildagliptin
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
MX2020010673A (es) Formulaciones de apixaban.
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
AU2017394032A8 (en) Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
PH12018502139A1 (en) Phosphaplatin liquid formulations
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
UA101533U (uk) Полівалентний оральний гель для лікування і профілактики післяімплантаційних ускладнень
ECSP17025904A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
MX2018004835A (es) Etilenglicol eter de buprenorfina.
MX2017001512A (es) Compuestos activos hacia bromodominios.